Abbott secures FDA clearance for two over-the-counter glucose monitors
Adds analyst comment in paragraphs 4 and 8, shares in paragraph 10
By Pratik Jain and Sriparna Roy
June 10 (Reuters) -Abbott Laboratories ABT.N said on Monday the U.S. health regulator had cleared the company's two new over-the-counter glucose monitoring devices, expanding its presence in a fast-growing, multi-billion-dollar market.
The devices, one for the health-conscious and another for those with diabetes, follow the company's FreeStyle Libre, which generates over $1 billion every quarter and is sold under prescription for patients with diabetes.
One of the new OTC devices, Libre Rio, targets people with type 2 diabetes who do not use insulin and typically manage their diabetes through lifestyle modifications.
The Food and Drug Administration's clearance for Libre Rio allows access to a continuous glucose monitor for 24.5 million type 2 diabetes patients who do not use insulin, RBC Capital Markets analyst Shagun Singh said.
The other product, Lingo, will help to track glucose and provide personalized insights to improve overall well-being.
Abbott plans to launch Lingo this summer, a spokesperson said, without disclosing details on pricing. The company said it would share details on pricing and availability of Libre Rio later.
Lingo is available in Britain since January for 120-150 pounds ($152-$190) per month.
Abbott believes the new devices combined can be at least a $1 billion plus in annual sales opportunity as a first stop, the RBC analyst said.
Libre Rio and Lingo will compete with Dexcom's DXCM.O Stelo, which in March became the first continuous glucose monitor to be approved by the FDA for OTC sales.
Shares of Abbott were up about 1% in morning trade.
Olympic athletes turn to diabetes tech in pursuit of medals https://www.reuters.com/sports/olympics/olympic-athletes-turn-diabetes-tech-pursuit-medals-2024-06-10/
Reporting by Sriparna Roy and Pratik Jain in Bengaluru; Editing by Shailesh Kuber and Maju Samuel
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
